Elevated blood markers 1 year before manifestation of malignant glioma

Neuro-Oncology

Volumn 12, Issue 9, 2010, Pages 1004-1008

  Gartner, Wolfgang ^a,b   Ilhan, Aysegül ^a   Neziri, Dashurie ^a   Base, Wolfgang ^a   Weissel, Michael ^a   Wöhrer, Adelheid ^c   Heinzl, Harald ^a   Waldhör, Thomas ^a   Wagner, Ludwig ^a   Preusser, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b St Vincent Hospital Vienna   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker; Blood; Glioma; Neurooncology

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FATTY ACID BINDING PROTEIN; GELATINASE B; NEUROPEPTIDE Y; PROTEIN S100B; SECRETAGOGIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BRAIN TISSUE; CANCER INCIDENCE; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BRAIN NEOPLASMS; CALCIUM-BINDING PROTEINS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; NEUROPEPTIDE Y; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77957932102     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq034     Document Type: Article

References (19)

1. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC Press; 2007.
2. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007;130(pt 12):3336-3341.
3. Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neurooncology. 2009;11(5):468-476.
4. Gartner W, Zierhut B, Mineva I, Sodeck G, Leutmezer F, Domanovits H, et al. Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions. Clin Biochem. 2008;41(18):1434- 1439.
5. Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95(3):401-411.
6. Gartner W, Lang W, Leutmetzer F, Domanovits H, Waldhausl W, Wagner L. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein. Cereb Cortex. 2001;11(12):1161-1169.
7. Camby I, Nagy N, Lopes MB, Schafer BW, Maurage CA, Ruchoux MM, et al. Supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins. Brain Pathol. 1999;9(1):1-19.
8. Allen JM, Hoyle NR, Yeats JC, Ghatei MA, Thomas DG, Bloom SR. Neuropeptides in neurological tumours. J Neurooncol. 1985;3(3):197-202.
9. Pipp I, Wagner L, Rossler K, Budka H, Preusser M. Secretagogin expression in tumours of the human brain and its coverings. APMIS. 2007;115(4):319-326.
10. Song WS, Guo LB, Hong ZY, Li JJ, Wu J. Serum S100 protein and radiation-induced brain injury in astrocytoma patients. Di Yi Jun Yi Da Xue Xue Bao. 2005;25(6):723-725.
11. Rajendra A, Spinella PC, Drott HR, Dominguez TE, Sutton L, Helfaer M. S-100beta protein-serum levels in children with brain neoplasms and its potential as a tumor marker. J Neurooncol. 2004;67(3): 345-349.
12. Vos MJ, Postma TJ, Martens F, Uitdehaag BM, Blankenstein MA, Vandertop WP, et al. Serum levels of S-100B protein and neuronspecific enolase in glioma patients: a pilot study. Anticancer Res. 2004;24(4):2511-2514.
13. Ortiz-Munoz B, Menendez-Lopez A, Yaya-Tur R, Arribas-Alpuente L, Maiquez-Richart J, Bordes-Monmeneu M. S100 protein in tumours of the central nervous system. Rev Neurol. 2003;36(11):1011-1015.
14. Hofer S, Kollias S, Weller M. Evolution of glioblastoma. Acta Oncol. 2009;48(4):630-631.
15. Okamoto K, Ito J, Takahashi N, Ishikawa K, Furusawa T, Tokiguchi S, et al. MRI of high-grade astrocytic tumors: early appearance and evolution. Neuroradiology. 2002;44(5):395-402.
16. Landy HJ, Lee TT, Potter P, Feun L, Markoe A. Early MRI findings in high grade glioma. J Neurooncol. 2000;47(1):65-72.
17. Caglar K, Kutluk T, Varan A, Koray Z, Akyuz C, Yalcin B, et al. Leptin and neuropeptide Y plasma levels in children with cancer. J Pediatr Endocrinol Metab. 2005;18(5):485-489.
18. Satoh C, Satoh F, Takahashi K, Murakami O, Sone M, Totsune K, et al. Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy. Endocr J. 1999;46(1):139-146.
19. Sedaghat F, Notopoulos A. S100 protein family and its application in clinical practice. Hippokratia. 2008;12(4):198-204.